Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
Sponsor: Mohsen Saidinejad
Summary
The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.
Official title: Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults: A Randomized Control Trial
Key Details
Gender
All
Age Range
5 Years - 20 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2026-04-01
Completion Date
2028-04-30
Last Updated
2026-03-09
Healthy Volunteers
No
Conditions
Interventions
Sub-dissociative Ketamine Infusion
0.25 mg/kg of IV ketamine within a 20-minute infusion of 100 milliliters of normal saline (NS)
Normal Saline Placebo Infusion
20-minute infusion of 100 milliliters of normal saline
Locations (1)
Harbor UCLA Medical Center
Torrance, California, United States